Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Preclinical Approach to Sensitize Multiple Myeloma Cells: Combination of the MEK Inhibitor PD0325901 with ABT-737 or Mevinolin.

Maria Rosaria Ricciardi, Elisabetta Calabrese, Michele Milella, Paola Bergamo, Samantha Decandia, Cinzia De Benedictis, Robin Foà, Agostino Tafuri, Maria Teresa Petrucci

Blood (2009) 114 (22): 1842.

https://doi.org/10.1182/blood.V114.22.1842.1842

Published: 2009

Journal Articles

Preclinical Study to Sensitize Acute Lymphoblastic Leukemia Primary Cells by Combined mTOR and BCL-2 Inhibition with CCI-779 and ABT-737.

Maria Rosaria Ricciardi, Samantha Decandia, Paola Bergamo, Cinzia De Benedictis, Antonella Vitale, Anna Maria Testi, Joanna Fei, Maria Teresa Petrucci, Michele Milella, Robin Foà, Agostino Tafuri

Blood (2009) 114 (22): 985.

https://doi.org/10.1182/blood.V114.22.985.985

Published: 2009

Journal Articles

Parallel Signaling through PI3K/AKT/mTOR Mediates Resistance to MEK Inhibition in Preclinical Models of Acute Myeloid Leukemia (AML): Synergistic Effects of Combined MEK and mTOR Inhibition.

Maria Rosaria Ricciardi, PhD, Twee Tsao, PhD, Stephen Lee Abrams, PhD, Paola Bergamo, MS, Linda S Steelman, BS., MS, Samantha Decandia, PhD, Lara Felicioni, PhD, Ludovica Ciuffreda, PhD, Cristina Di Sanza, PhD, Antonio Marchetti, MD, PhD, Francesco Cognetti, MD, James McCubrey, PhD, Marina Konopleva, MD, PhD, Michael Andreeff, MD, PhD, Agostino Tafuri, MD, Michele Milella, MD

Blood (2009) 114 (22): 594.

https://doi.org/10.1182/blood.V114.22.594.594

Published: 2009

Journal Articles

Simultaneous Targeting of Bcl-2/Bcl-Xl and MEK/ERK Results in Highly Synergistic Induction of Apoptosis in Human AML, Both in Vitro and In Vivo.

Marina Konopleva, MD, PhD, Michele Milella, MD, Julie C Watts, PhD, Maria Rosaria Ricciardi, PhD, Borys Korchin, PhD, Twee Tsao, PhD, Paola Bergamo, MS, Duncan H. Mak, PhD, Samantha Decandia, PhD, James McCubrey, PhD, Agostino Tafuri, MD, Michael Andreeff, MD, PhD

Blood (2009) 114 (22): 2757.

https://doi.org/10.1182/blood.V114.22.2757.2757

Published: 2009

Journal Articles

Development of Mek inhibition (MEK-I)-Based Therapeutic Strategies in Acute Myeloid Leukemia (AML)

Michele Milella, MD, Maria Rosaria Ricciardi, Paola Bergamo, MS, Maria Cristina Scerpa, PhD, Jacopo Gervasoni, MS, Maria Teresa Petrucci, MD, Sabina Chiaretti, MD, Simona Tavolaro, MS, Ludovica Ciuffreda, PhD, Samantha Decandia, Francesco Libotte, Stephen Lee Abrams, Linda S Steelman, BS., MS, Marina Konopleva, MD, PhD, Francesco Cognetti, MD, Robert Foa, Michael Andreeff, MD, PhD, James McCubrey, PhD, Agostino Tafuri

Blood (2008) 112 (11): 860.

https://doi.org/10.1182/blood.V112.11.860.860

Published: 2008

Journal Articles

BCL-2/BCL-XL Inhibition in Smoldering Multiple Myeloma CD138+ Cells: Functional Effects and Protein Expression Levels

Francesco Libotte, Maria Rosaria Ricciardi, Elisabetta Calabrese, Cinzia De Benedictis, Sara Santinelli, Paola Bergamo, Samantha Decandia, Anna Levi, Ali Fathi Mohamad, Vincenzo Federico, Michele Milella, Robert Foà, Agostino Tafuri, Maria Teresa Petrucci

Blood (2008) 112 (11): 5159.

https://doi.org/10.1182/blood.V112.11.5159.5159

Published: 2008

Journal Articles

Synergistic Induction of Apoptosis in Multiple Myeloma Cells by Simultaneous Inhibition of the Raf/MEK/ERK and BCL-2 Pathways

Maria Rosaria Ricciardi, Michele Milella, Francesco Libotte, Elisabetta Calabrese, Paola Bergamo, Sara Santinelli, Samantha Decandia, Cinzia De Benedictis, Anna Levi, Robert Foà, Agostino Tafuri, Maria Teresa Petrucci

Blood (2008) 112 (11): 5161.

https://doi.org/10.1182/blood.V112.11.5161.5161

Published: 2008

Journal Articles

Multiple Strategies Based on MEK, mTOR and BCL-2 Signal Transduction Inhibition in Acute Lymphoblastic Leukemia (ALL)

Maria Rosaria Ricciardi, PhD, Samantha Decandia, Sara Santinelli, Chiara Gregorj, Fabiana De Cave, Maria Cristina Scerpa, PhD, Paola Bergamo, MS, Francesco Libotte, Cinzia De Benedictis, Antonella Vitale, Maria Teresa Petrucci, MD, Marina Konopleva, MD, PhD, Michael Andreeff, MD, PhD, Michele Milella, Robert Foa, Agostino Tafuri

Blood (2008) 112 (11): 5034.

https://doi.org/10.1182/blood.V112.11.5034.5034

Published: 2008

Journal Articles

Protein Expression of p15 and p21 Plays an Unfavorable Prognostic Role in Adult Acute Lymphoblastic Leukemia (ALL) Patients Independently of Their Gene Promoter Methylation Status.

Blood (2007) 110 (11): 2802.

https://doi.org/10.1182/blood.V110.11.2802.2802

Published: 2007

Journal Articles

The BCL-2 Antagonist ABT-737 Is Highly Effective on Primary Acute Lymphoblastic Leukemia Cells.

Maria Rosaria Ricciardi, PhD, Chiara Gregorj, PhD, Fabiana De Cave, MS, Paola Bergamo, Samantha Decandia, MS, Sara Santinelli, Antonella Vitale, MD, Maria Teresa Petrucci, MD, Michele Milella, MD, Robert Foa, MD, Agostino Tafuri, MD

Blood (2007) 110 (11): 155.

https://doi.org/10.1182/blood.V110.11.155.155

Published: 2007

Journal Articles

Functional Effects of the Bcl-2/Bcl-xL Inhibitor ABT-737 on Primary Cells from Smoldering Multiple Myeloma.

Maria Rosaria Ricciardi, PhD, Elisabetta Calabrese, MD, Fabiana De Cave, PhD, Sara Santinelli, Paola Bergamo, Samantha Decandia, PhD, Chiara Gregorj, PhD, Vincenzo Federico, MD, Michele Milella, MD, Robert Foa, MD, Agostino Tafuri, MD, Maria Teresa Petrucci, MD

Blood (2007) 110 (11): 4782.

https://doi.org/10.1182/blood.V110.11.4782.4782

Published: 2007

NARROW

Preclinical Approach to Sensitize Multiple Myeloma Cells: Combination of the MEK Inhibitor PD0325901 with ABT-737 or Mevinolin.

Preclinical Study to Sensitize Acute Lymphoblastic Leukemia Primary Cells by Combined mTOR and BCL-2 Inhibition with CCI-779 and ABT-737.

Parallel Signaling through PI3K/AKT/mTOR Mediates Resistance to MEK Inhibition in Preclinical Models of Acute Myeloid Leukemia (AML): Synergistic Effects of Combined MEK and mTOR Inhibition.

Simultaneous Targeting of Bcl-2/Bcl-Xl and MEK/ERK Results in Highly Synergistic Induction of Apoptosis in Human AML, Both in Vitro and In Vivo.

Development of Mek inhibition (MEK-I)-Based Therapeutic Strategies in Acute Myeloid Leukemia (AML)

BCL-2/BCL-XL Inhibition in Smoldering Multiple Myeloma CD138+ Cells: Functional Effects and Protein Expression Levels

Synergistic Induction of Apoptosis in Multiple Myeloma Cells by Simultaneous Inhibition of the Raf/MEK/ERK and BCL-2 Pathways

Multiple Strategies Based on MEK, mTOR and BCL-2 Signal Transduction Inhibition in Acute Lymphoblastic Leukemia (ALL)

Protein Expression of p15 and p21 Plays an Unfavorable Prognostic Role in Adult Acute Lymphoblastic Leukemia (ALL) Patients Independently of Their Gene Promoter Methylation Status.

The BCL-2 Antagonist ABT-737 Is Highly Effective on Primary Acute Lymphoblastic Leukemia Cells.

Functional Effects of the Bcl-2/Bcl-xL Inhibitor ABT-737 on Primary Cells from Smoldering Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only